Diligence memo · auto-generated · as of July 2, 2026
Vibliome Therapeutics, Llc
Vibliome Therapeutics, Llc looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Vibliome Therapeutics, Llc operates in Pharma, based in BOZEMAN.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Vibliome Therapeutics, Llc has raised $8.0M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $8.0M on 2019-02-13.
Most recent recorded round closed around 2019-02-13.
Valuation (modeled)modeled
Provath models Vibliome Therapeutics, Llc at approximately $248M (range $9.2M–$1.3B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.30× the median modeled value of Series A Pharma companies in 2019–2021 (24 peers) — value vs value, same stage and era. Within the normal band (130% of peer median) for its niche.
Financing rhythm & timingmixed
Last raise 7.4 yr ago; this sector typically re-raises about every 16 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 62% of Pharma peers (310 compared).
Modeled value ranks above 80% of those peers.
Closest niche peers: Comet Therapeutics, Inc., RadImmune Therapeutics, Inc., Nanoscope Therapeutics, Inc., ZebiAI Therapeutics, Inc., Blue Note Therapeutics, Inc..
Peoplefiled
7 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.